Literature DB >> 16880481

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.

R M Post1, L L Altshuler, G S Leverich, M A Frye, W A Nolen, R W Kupka, T Suppes, S McElroy, P E Keck, K D Denicoff, H Grunze, J Walden, C M R Kitchen, J Mintz.   

Abstract

BACKGROUND: Few studies have examined the relative risks of switching into hypomania or mania associated with second-generation antidepressant drugs in bipolar depression. AIMS: To examine the relative acute effects of bupropion, sertraline and venlafaxine as adjuncts to mood stabilisers.
METHOD: In a 10-week trial, participants receiving out-patient treatment for bipolar disorder (stratified for rapid cycling) were randomly treated with a flexible dose of one of the antidepressants, or their respective matching placebos, as adjuncts to mood stabilisers.
RESULTS: A total of 174 adults with bipolar disorder I, II or not otherwise specified, currently in the depressed phase, were included. All three antidepressants were associated with a similar range of acute response (49-53%) and remission (34-41%). There was a significantly increased risk of switches into hypomania or mania in participants treated with venlafaxine compared with bupropion or sertraline.
CONCLUSIONS: More caution appears indicated in the use of venlafaxine rather than bupropion or sertraline in the adjunctive treatment of bipolar depression, especially if there is a prior history of rapid cycling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880481     DOI: 10.1192/bjp.bp.105.013045

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  62 in total

1.  The continuum of unipolar depression − bipolar II depression - bipolar I depression: different treatments indicated?

Authors:  Willem A Nolen
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

2.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

Review 3.  New findings from the Bipolar Collaborative Network: clinical implications for therapeutics.

Authors:  Robert M Post; Lori L Altshuler; Mark A Frye; Trisha Suppes; Susan McElroy; Paul E Keck; Gabriele S Leverich; Ralph Kupka; Willem A Nolen; Heinz Grunze
Journal:  Curr Psychiatry Rep       Date:  2006-12       Impact factor: 5.285

4.  Bipolarity is important during treatment with antidepressants.

Authors:  Daniel J Smith; James T Walters
Journal:  BMJ       Date:  2007-02-17

Review 5.  Review of evidence for use of antidepressants in bipolar depression.

Authors:  Shane J McInerney; Sidney H Kennedy
Journal:  Prim Care Companion CNS Disord       Date:  2014-10-16

Review 6.  Switching to hypomania and mania: differential neurochemical, neuropsychological, and pharmacologic triggers and their mechanisms.

Authors:  Jun Chen; Yiru Fang; David E Kemp; Joseph R Calabrese; Keming Gao
Journal:  Curr Psychiatry Rep       Date:  2010-12       Impact factor: 5.285

Review 7.  Preventative strategies for early-onset bipolar disorder: towards a clinical staging model.

Authors:  Robert K McNamara; Jayasree J Nandagopal; Stephen M Strakowski; Melissa P DelBello
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

8.  Treatment of refractory bipolar depression.

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

Review 9.  STEP-BD and bipolar depression: what have we learned?

Authors:  Michael E Thase
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

10.  Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders.

Authors:  Andrew C Leon; Jess G Fiedorowicz; David A Solomon; Chunshan Li; William H Coryell; Jean Endicott; Jan Fawcett; Martin B Keller
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.